Acute hemolytic vascular inflammatory processes are prevented by nitric oxide replacement or a single dose of hydroxyurea
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Key Points: Hemolytic processes induce rapid systemic and vascular inflammation in C57BL/6 mice that is abolished by a single dose of hydroxyurea (HU). HU exerts some NO-dependent effects and should be investigated as an acute treatment of SCD and for other hemolytic disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dose translation from animal to human studies revisited.
Reagan‐Shaw, S., Nihal, M., & Ahmad, N. (2008) · The FASEB Journal · doi:10.1096/fj.07-9574lsf · Cited by 6,524
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia
Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V., McMahon, R. P., & Bonds, D. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322001 · Cited by 2,340 · cited 1×
“3 of action of HU in SCD is believed to be its ability to induce the production of fetal Hb (HbF) in erythrocytes, reducing HbS polymerization and red cell sickling.(18,19) However,”
BackgroundCell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease
Reiter, C. D., Wang, X., Tanus-Santos, J. E., Hogg, N., Cannon, R. O., Schechter, A. N., & Gladwin, M. T. (2002) · Nature Medicine · doi:10.1038/nm1202-799 · Cited by 1,330
Schaer, D. J., Buehler, P. W., Alayash, A. I., Belcher, J. D., & Vercellotti, G. M. (2013) · Blood · doi:10.1182/blood-2012-11-451229 · Cited by 754
Belcher, J. D., Chen, C., Nguyen, J., Milbauer, L., Abdulla, F., Alayash, A. I., Smith, A., Nath, K. A., Hebbel, R. P., & Vercellotti, G. M. (2014) · Blood · doi:10.1182/blood-2013-04-495887 · Cited by 695 · cited 3×
“Furthermore, once oxidized, hemoglobin releases hemin, a hydrophobic molecule recently demonstrated to induce neutrophil extracellular trap (NET) production,(11) and cause toll-like receptor (TLR)-4mediated stasis in murine SCD.(12) As such, hemolysis constitutes a major disease mechanism, and failure to neutralize CF…”
BackgroundMethodHeme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease
Chen, G., Zhang, D., Fuchs, T. A., Manwani, D., Wagner, D. D., & Frenette, P. S. (2014) · Blood · doi:10.1182/blood-2013-10-529982 · Cited by 354
Hemolysis-induced lethality involves inflammasome activation by heme
Dutra, F. F., Alves, L. S., Rodrigues, D., Fernandez, P. L., de Oliveira, R. B., Golenbock, D. T., Zamboni, D. S., & Bozza, M. T. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1405023111 · Cited by 353
Heme Degradation and Vascular Injury
Belcher, J. D., Beckman, J. D., Balla, G., Balla, J., & Vercellotti, G. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2822 · Cited by 257
Porto, B. N., Alves, L. S., Fernández, P. L., Dutra, T. P., Figueiredo, R. T., Graça-Souza, A. V., & Bozza, M. T. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703570200 · Cited by 161
Pathology of Berkeley sickle cell mice: similarities and differences with human sickle cell disease
Manci, E. A. (2006) · Blood · doi:10.1182/blood-2005-07-2839 · Cited by 149 · cited 1×
“These findings probably reflect the decreased osmotic fragility of sickle RBC(39) and the fact that BERK SCD mice already demonstrate high levels of intravascular hemolysis.(40) While others have successfully demonstrated the direct inflammatory effects of hemin administration in vivo,(11,12,38) we opted to employ int…”
Background
Research works printed but not linked: 41
- Olsson, 2012, Pathological conditions involving extracellular hemoglobin: molecular mechanisms, clinical significance, and novel therapeutic opportunities for α(1)-microglobulin., Antioxid Redox Signal, 17, 813, 10.1089/ars.2011.4282 · DOI
- Wood, 2008, Sickle cell disease vasculopathy: a state of nitric oxide resistance., Free Radic Biol Med, 44, 1506, 10.1016/j.freeradbiomed.2008.01.008 · DOI · Paper page
- Yeo, 2009, Relationship of cell-free hemoglobin to impaired endothelial nitric oxide bioavailability and perfusion in severe falciparum malaria., J Infect Dis, 200, 1522, 10.1086/644641 · DOI · Paper page
- Vermeulen Windsant, 2012, Blood transfusions increase circulating plasma free hemoglobin levels and plasma nitric oxide consumption: a prospective observational pilot study., Crit Care, 16, R95, 10.1186/cc11359 · DOI
- Graça-Souza, 2002, Neutrophil activation by heme: implications for inflammatory processes., Blood, 99, 4160, 10.1182/blood.V99.11.4160 · DOI · Paper page
- Rother, 2005, The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease., JAMA, 293, 1653, 10.1001/jama.293.13.1653 · DOI · Paper page
- Vinchi, 2013, Hemopexin therapy improves cardiovascular function by preventing heme-induced endothelial toxicity in mouse models of hemolytic diseases., Circulation, 127, 1317, 10.1161/CIRCULATIONAHA.112.130179 · DOI · Paper page
- Conran, 2014, Intravascular hemolysis: a disease mechanism not to be ignored., Acta Haematol, 132, 97, 10.1159/000356836 · DOI
- De Forni, 2010, Strategies to improve efficacy and safety of a novel class of antiviral hyper-activation-limiting therapeutic agents: the VS411 model in HIV/AIDS., Br J Pharmacol, 161, 830, 10.1111/j.1476-5381.2010.00940.x · doi:10.1111/j.1476-5381.2010.00940.x
- Barbui, 2012, Front-line therapy in polycythemia vera and essential thrombocythemia., Blood Rev, 26, 205, 10.1016/j.blre.2012.06.002 · DOI
- Cervantes, 2014, How I treat myelofibrosis., Blood, 124, 2635, 10.1182/blood-2014-07-575373 · DOI · Paper page
- McGann, 2011, Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain?, Curr Opin Hematol, 18, 158, 10.1097/MOH.0b013e32834521dd · DOI · Paper page
- Goldberg, 1990, Treatment of sickle cell anemia with hydroxyurea and erythropoietin., N Engl J Med, 323, 366, 10.1056/NEJM199008093230602 · DOI · Paper page
- Ware, 2010, How I use hydroxyurea to treat young patients with sickle cell anemia., Blood, 115, 5300, 10.1182/blood-2009-04-146852 · DOI · Paper page
- Charache, 1996, Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive “switching” agent., Medicine (Baltimore), 75, 300, 10.1097/00005792-199611000-00002 · DOI · Paper page
- Gladwin, 2002, Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease., Br J Haematol, 116, 436, 10.1046/j.1365-2141.2002.03274.x · DOI · Paper page
- Glover, 1999, Detection of nitrosyl hemoglobin in venous blood in the treatment of sickle cell anemia with hydroxyurea., Mol Pharmacol, 55, 1006, 10.1124/mol.55.6.1006 · DOI · Paper page
- Nahavandi, 2000, Nitric Oxide Metabolites in Sickle Cell Anemia Patients after Oral Administration of Hydroxyurea; Hemoglobinopathy., Hematology, 5, 335, 10.1080/10245332.2000.11746528 · DOI · Paper page
- Ignarro, 1987, Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical., Circ Res, 61, 866, 10.1161/01.RES.61.6.866 · DOI · Paper page
- Canalli, 2008, Increased adhesive properties of neutrophils in sickle cell disease may be reversed by pharmacological nitric oxide donation., Haematologica, 93, 605, 10.3324/haematol.12119 · DOI · Paper page
- Almeida, 2012, Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice., Blood, 120, 2879, 10.1182/blood-2012-02-409524 · DOI · Paper page
- Turhan, 2002, Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm., Proc Natl Acad Sci USA, 99, 3047, 10.1073/pnas.052522799 · DOI · Paper page
- Fairbanks, 1992, Methods for measuring plasma hemoglobin in micromolar concentration compared., Clin Chem, 38, 132, 10.1093/clinchem/38.1.132 · DOI
- Kaul, 2004, Anti-inflammatory therapy ameliorates leukocyte adhesion and microvascular flow abnormalities in transgenic sickle mice., Am J Physiol Heart Circ Physiol, 287, H293, 10.1152/ajpheart.01150.2003 · DOI · Paper page
- Senchenkov, 2011, P-selectin mediates the microvascular dysfunction associated with persistent cytomegalovirus infection in normocholesterolemic and hypercholesterolemic mice., Microcirculation, 18, 452, 10.1111/j.1549-8719.2011.00106.x · DOI
- Neumann, 1997, Induction of acute inflammatory lung injury by staphylococcal enterotoxin B., J Immunol, 158, 1862, 10.4049/jimmunol.158.4.1862 · doi:10.4049/jimmunol.158.4.1862
- Chang, 2008, Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion., Blood, 111, 915, 10.1182/blood-2007-04-084061 · DOI · Paper page
- Berra, 2014, Autologous transfusion of stored red blood cells increases pulmonary artery pressure., Am J Respir Crit Care Med, 190, 800, 10.1164/rccm.201405-0850OC · DOI
- Yoong, 2003, Binding of ovarian steroids to erythrocytes in patients with sickle cell disease; effects on cell sickling and osmotic fragility., J Steroid Biochem Mol Biol, 84, 71, 10.1016/S0960-0760(02)00266-2 · DOI
- Minneci, 2005, Hemolysis-associated endothelial dysfunction mediated by accelerated NO inactivation by decompartmentalized oxyhemoglobin., J Clin Invest, 115, 3409, 10.1172/JCI25040 · DOI · Paper page
- Qutub, 2010, Interactions of hemin with model erythrocyte membranes., J Phys Chem B, 114, 4529, 10.1021/jp100611n · DOI
- Steinberg, 2010, The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up., Am J Hematol, 85, 403, 10.1002/ajh.21699 · DOI · Paper page
- King, 2004, Nitric oxide production from hydroxyurea., Free Radic Biol Med, 37, 737, 10.1016/j.freeradbiomed.2004.02.073 · DOI
- Cokic, 2006, Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells., Blood, 108, 184, 10.1182/blood-2005-11-4454 · DOI
- Cokic, 2008, Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells., Blood, 111, 1117, 10.1182/blood-2007-05-088732 · DOI · Paper page
- Xu, 2011, Hydroxyurea enhances SMN2 gene expression through nitric oxide release., Neurogenetics, 12, 19, 10.1007/s10048-010-0268-z · DOI
- Kato, 2009, Endogenous nitric oxide synthase inhibitors in sickle cell disease: abnormal levels and correlations with pulmonary hypertension, desaturation, haemolysis, organ dysfunction and death., Br J Haematol, 145, 506, 10.1111/j.1365-2141.2009.07658.x · DOI
- Conran, 2003, Nitric oxide has a role in regulating VLA-4-integrin expression on the human neutrophil cell surface., Biochem Pharmacol, 66, 43, 10.1016/S0006-2952(03)00243-0 · doi:10.1016/s0006-2952(03)00243-0
- Conran, 2001, Nitric oxide regulates human eosinophil adhesion mechanisms in vitro by changing integrin expression and activity on the eosinophil cell surface., Br J Pharmacol, 134, 632, 10.1038/sj.bjp.0704295 · doi:10.1038/sj.bjp.0704295
- Qian, 2012, Exogenous, but not Endogenous Nitric Oxide Inhibits Adhesion Molecule Expression in Human Endothelial Cells., Front Physiol, 3, 3, 10.3389/fphys.2012.00003 · DOI
- El Nemer, 2012, HU for acute treatment of sickle VOC?, Blood, 120, 2777, 10.1182/blood-2012-08-447102 · DOI
Cited by
Pathophysiology of Sickle Cell Disease
Sundd, P., Gladwin, M. T., & Novelli, E. M. (2019) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-012838 · Cited by 813
Intravascular hemolysis and the pathophysiology of sickle cell disease
Kato, G. J., Steinberg, M. H., & Gladwin, M. T. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89741 · Cited by 748
Ware, R. E., Davis, B. R., Schultz, W. H., Brown, R. C., Aygun, B., Sarnaik, S., Odame, I., Fuh, B., George, A., Owen, W., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01041-7 · Cited by 515
Inflammation in sickle cell disease
Conran, N., & Belcher, J. D. (2018) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-189012 · Cited by 294
Self-citationCardiovascular complications and risk of death in sickle-cell disease
Gladwin, M. T. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00647-4 · Cited by 164
Metadata
- Authors
- Almeida, C. B., Souza, L. E. B., Leonardo, F. C., Costa, F. T. M., Werneck, C. C., Covas, D. T., Costa, F. F., & Conran, N.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2015-08-06
- Volume
- 126
- Issue
- 6
- Pages
- 711-720
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2166262520
- Cited by
- 82
- References
- 11
- FWCI
- 6.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Acute hemolytic vascular inflammatory processes are prevented by nitric oxide replacement or a single dose of hydroxyurea. https://app.cochat.ai/papers/10.1182/blood-2014-12-616250
- The paper
- Almeida, C. B., Souza, L. E. B., Leonardo, F. C., Costa, F. T. M., Werneck, C. C., Covas, D. T., Costa, F. F., & Conran, N. (2015). Acute hemolytic vascular inflammatory processes are prevented by nitric oxide replacement or a single dose of hydroxyurea. Blood. https://doi.org/10.1182/blood-2014-12-616250
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.